A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

Inclusion Criteria: * Normotensive male or female volunteers, with a body mass index of 18.0-30.0 kg/m2. * Deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine. * Agree to follow the contraception requirements of the trial. * Able to give fully informed written consent. * Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication. Exclusion Criteria: * History or presence of iron deficiency or iron deficiency anaemia and/or currently receiving oral or parenteral iron supplementation as treatment for those conditions. * Positive tests for hepatitis B \& C, HIV * Drug or alcohol abuse. * Smoke more than 10 cigarettes (or equivalent) daily. * Use of over-the-counter medication (with the exception of paracetamol \[acetaminophen\]) during the 7 days before the first dose of trial medication, or prescribed medication (with the exception of hormone replacement therapy \[HRT\]) during the 28 days before first dose of trial medication. * Use of supplement(s) during the 28 days before screening. * Participation in other clinical trials of unlicensed medicines, or loss of more than 400 mL blood, within the previous 3 months. * Clinically relevant abnormal medical history or concurrent medical condition. * Pre-menopausal females who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception.